Sign Out
Therapy with JADENU should be initiated and maintained by physicians experience in the treatment of chronic iron overload due to blood transfusions.
Deferasirox is contraindicated in patients with moderate and severe renal impairment (see Contraindications) and has not been studied in patients with severe hepatic impairment.
The following are clinically significant adverse events: Acute renal failure; Hepatic failure; Gastrointestinal haemorrhage and perforations.
JADENU is a strength-adjusted formulation of deferasirox with higher bioavailability compared to EXJADE dispersible tablets. JADENU requires a different dosing regimen and method of administration compared to EXJADE. To avoid dosing errors, it is important that prescriptions of deferasirox specify both the type of formulation (dispersible tablet or film-coated tablet) and the prescribed dose in mg/kg/day.
